2-[[(Z)-docos-13-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-[[(Z)-docos-13-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
• 化学式: C27H57NO4P+
• 分子量: 490.7
• InChiKey: KCRSJPCXPQESIU-SEYXRHQNSA-O

计算性质

• 辛醇/水分配系数(LogP)：
  9.1
• 重原子数：
  33
• 可旋转键数：
  25
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.93
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Novel alkyl phospholipid derivatives and uses thereof
  申请人：Zentaris GmbH

  公开号：EP1800684A1

  公开（公告）日：2007-06-27

  The present invention provides novel alkyl phospholipid derivatives that are useful for treating various diseases including tumors and/or pathophysiological conditions in mammals, preferably humans, that are caused by microorganisms, in particular fungi, protozoa, bacteria and/or viruses. Such alkyl phospholipids can be employed as single drugs or in the course of combination therapies, in particular for the treatment of leishmaniasis, trypanosomiasis and/or malaria.

  本发明提供了新型烷基磷脂衍生物，可用于治疗包括肿瘤和/或哺乳动物（尤其是人类）中由微生物，特别是真菌、原虫、细菌和/或病毒引起的各种疾病，这些烷基磷脂可作为单一药物或结合疗法的一部分，特别是用于治疗利什曼病、锥虫病和/或疟疾。
• [EN] METHODS FOR TREATING CANCER<br/>[FR] MÉTHODES DE TRAITEMENT DU CANCER
  申请人：SCORPION THERAPEUTICS INC

  公开号：WO2022094271A1

  公开（公告）日：2022-05-05

  This disclosure provides chemical entities of formula (I) (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/ or cocrystal, and/or drug combination of the compound) that inhibit epidermal growth factor receptor (EGFR, ERBB 1) and/or Human epidermal growth factor receptor 2 (HER2, ERBB2). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) EGFR and/or HER2 activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.

  本公开提供化学实体的公式（I）（例如，化合物或药学上可接受的盐，和/或水合物，和/或共晶体，和/或该化合物的药物组合），该化学实体可以抑制表皮生长因子受体（EGFR，ERBB1）和/或人类表皮生长因子受体2（HER2，ERBB2）。这些化学实体是有用的，例如，用于治疗某种情况，疾病或障碍，其中EGFR和/或HER2的增加（例如过度）对病理学和/或症状和/或情况，疾病或障碍的进展有贡献（例如癌症）在受试者（例如人类）中。本公开还提供包含相同物质的组合物以及使用和制备相同物质的方法。
• [EN] USE OF MACROCYCLIC COMPOUNDS IN METHODS OF TREATING CANCER<br/>[FR] UTILISATION DE COMPOSÉS MACROCYCLIQUES DANS DES MÉTHODES DE TRAITEMENT DE CANCER
  申请人：SCORPION THERAPEUTICS INC

  公开号：WO2022098992A1

  公开（公告）日：2022-05-12

  This disclosure provides chemical entities (e.g., a compound or a pharmaceutically acceptable salt, and/or hydrate, and/or cocrystal, and/or drug combination of the compound) that inhibit epidermal growth factor receptor (EGFR, ERBB1) and/or Human epidermal growth factor receptor 2 (HER2, ERBB2). These chemical entities are useful, e.g., for treating a condition, disease or disorder in which increased (e.g., excessive) EGFR and/or HER2 activation contributes to the pathology and/or symptoms and/or progression of the condition, disease or disorder (e.g., cancer) in a subject (e.g., a human). This disclosure also provides compositions containing the same as well as methods of using and making the same.

  本公开提供化合物（例如，化合物或药物可接受的盐，和/或水合物，和/或共晶体，和/或化合物的药物组合物），其抑制表皮生长因子受体（EGFR，ERBB1）和/或人类表皮生长因子受体2（HER2，ERBB2）。这些化合物是有用的，例如，用于治疗某种情况，疾病或障碍，在该情况，疾病或障碍中增加（例如过度）的EGFR和/或HER2激活对该情况，疾病或障碍的病理生理和/或症状和/或进展有贡献的受试者（例如，人类）。本公开还提供包含相同物质的组合物以及使用和制备相同物质的方法。
• METHODS AND MATERIALS FOR ASSESSING AND TREATING CANCER
  申请人：The Johns Hopkins University

  公开号：EP3665308A1

  公开（公告）日：2020-06-17
• EP3749695A1
  申请人：——

  公开号：EP3749695A1

  公开（公告）日：2020-12-16